Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice.
Manuela HarloffSally PrüschenkRoland SeifertJens SchlossmannPublished in: British journal of pharmacology (2021)
Activation of the NO/sGC/PKG pathway with cinaciguat was beneficial in a model of diabetic nephropathy. Activators of sGC might be an appropriate therapy option in patients with Type 1 diabetes.
Keyphrases